Tardive Dyskinesia TD as a neurological disorder resulting in involuntary repetitive movement disorder as a disease of brain ...

Indivior, leader in opioid treatment, trades near 52-week lows. Read more on INDV stock's financials, growth challenges, and ...

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ ...

It is also used to treat tardive dyskinesia, another form of movement disorder. Sales were $638 million last year and according to Teva will approach the $1 billion mark in 2021, despite the ...

If you have tardive dyskinesia, or TD, try these tips for managing symptoms and living better every day.

Biosciences announced the appointment of Sanjay Keswani, M.D., to the company’s executive management team as Chief Medical ...

UBS analyst Ashwani Verma lowered the firm’s price target on Neurocrine (NBIX) to $137 from $154 and keeps a Buy rating on the shares. The ...

Metoclopramide is used for the symptomatic treatment of post-operative or chemotherapy-induced nausea and vomiting, gastroesophageal reflux disease and gastroparesis. Metoclopramide is generally ...

Neurocrine Biosciences, Inc. today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...